Skip to main content
Erschienen in: Journal of Genetic Counseling 6/2017

30.06.2017 | Original Research

Is Low FMR1 CGG Repeat Length in Males Correlated with Family History of BRCA-Associated Cancers? An Exploratory Analysis of Medical Records

verfasst von: Hallee C. Adamsheck, Elizabeth M. Petty, Jinkuk Hong, Mei W. Baker, Murray H. Brilliant, Marsha R. Mailick

Erschienen in: Journal of Genetic Counseling | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

The FMR1 gene has been studied extensively with regard to expansions and premutations, but much less research has focused on potential effects of low CGG repeat length. Previous studies have demonstrated that BRCA1/2 positive women are more likely to have an FMR1 genotype with one low CGG allele, and that women with both FMR1 alleles in the low CGG repeat range are more likely to have had breast cancer compared to women with normal numbers of CGG repeats. However, there has been no research as to whether low CGG repeat length impacts cancer risks in men. Therefore, this study aimed to examine cancer incidence and related risk factors in men with low CGG repeat length in the FMR1 gene. We utilized subject data from the Marshfield Personalized Medicine Research Project to compare cancer-related diagnoses between 878 males with low CGG repeat length (< 24 repeats) and 368 male controls with CGG repeats in the normal range (24 to 40 repeats). We utilized ICD-9 codes to examine various cancer diagnoses, family histories of cancer, other non-malignant neoplasms, cancer surveillance, and genetic susceptibility. Men with low CGG repeats were identified to have significantly higher rates of family history of any cancer type (p = 0.011), family history of any BRCA-associated cancer (p = 0.002), and specifically, family history of prostate cancer (p = 0.007). The mean number of BRCA-associated cancer diagnoses (breast, prostate, pancreatic, and melanoma) per individual in the low CGG group was slightly higher than that of the control group, with this difference trending toward significance (p = 0.091). Additionally, men with low CGG repeats had significantly higher rates of connective/soft tissue neoplasms (p = 0.026). Additional research is needed to replicate the observations reported in this preliminary exploratory study, particularly including verification of ICD-9 codes and family history by a genetic counselor.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Brown, W. T. (2002). The molecular biology of the fragile X mutation. In R. J. Hagerman & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment and research (3rd ed., pp. 110–135). Baltimore: Johns Hopkins University Press. Brown, W. T. (2002). The molecular biology of the fragile X mutation. In R. J. Hagerman & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment and research (3rd ed., pp. 110–135). Baltimore: Johns Hopkins University Press.
Zurück zum Zitat Cavanagh, H., & Rogers, K. M. A. (2015). The role of BRCA1 and BRCA2 mutations in prostate, pancreatic, and stomach cancers. Hereditary Cancer and Clinical. Practice, 13, 16.CrossRef Cavanagh, H., & Rogers, K. M. A. (2015). The role of BRCA1 and BRCA2 mutations in prostate, pancreatic, and stomach cancers. Hereditary Cancer and Clinical. Practice, 13, 16.CrossRef
Zurück zum Zitat Dagan, E., Cohen, Y., Mory, A., Adir, V., Borochowitz, Z., Raanani, H., et al. (2013). BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study. European Journal of Human Genetics, 22, 277–279.CrossRefPubMedPubMedCentral Dagan, E., Cohen, Y., Mory, A., Adir, V., Borochowitz, Z., Raanani, H., et al. (2013). BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study. European Journal of Human Genetics, 22, 277–279.CrossRefPubMedPubMedCentral
Zurück zum Zitat Fiederling, J., Shams, A. Z., & Haug, U. (2016). Validity of self-reported family history of cancer: a systematic literature review on selected cancers. International Journal of Cancer, 139, 1449–1460.CrossRefPubMed Fiederling, J., Shams, A. Z., & Haug, U. (2016). Validity of self-reported family history of cancer: a systematic literature review on selected cancers. International Journal of Cancer, 139, 1449–1460.CrossRefPubMed
Zurück zum Zitat Gleicher, N., Weghofer, A., & Barad, D. H. (2010). Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reproductive Biomedicine Online, 20, 768–775.CrossRefPubMed Gleicher, N., Weghofer, A., & Barad, D. H. (2010). Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing. Reproductive Biomedicine Online, 20, 768–775.CrossRefPubMed
Zurück zum Zitat Gleicher, N., McAlpine, J. N., Gilks, C. B., Kushnir, V. A., Lee, H. J., Wu, Y. G., et al. (2014a). Absence of BRCA/FMR1 correlations in women with ovarian cancers. PloS One, 9, 1–8.CrossRef Gleicher, N., McAlpine, J. N., Gilks, C. B., Kushnir, V. A., Lee, H. J., Wu, Y. G., et al. (2014a). Absence of BRCA/FMR1 correlations in women with ovarian cancers. PloS One, 9, 1–8.CrossRef
Zurück zum Zitat Gleicher, N., Weghofer, A., & Barad, D. H. (2014b). Do BRCA1/2 mutations and low FMR1 alleles interact or not? European Journal of Human Genetics, 22, 155–156.CrossRefPubMed Gleicher, N., Weghofer, A., & Barad, D. H. (2014b). Do BRCA1/2 mutations and low FMR1 alleles interact or not? European Journal of Human Genetics, 22, 155–156.CrossRefPubMed
Zurück zum Zitat Howlader, N., Noone, A. M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S. F., et al. (2014). SEER cancer statistics review, 1975–2011. Bethesda: National Cancer Institute. Howlader, N., Noone, A. M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S. F., et al. (2014). SEER cancer statistics review, 1975–2011. Bethesda: National Cancer Institute.
Zurück zum Zitat Kerber, R. A., & Slattery, M. L. (1997). Comparison of self-reported and database-linked family history of cancer data in a case-control study. American Journal of Epidemiology, 146, 244–248.CrossRefPubMed Kerber, R. A., & Slattery, M. L. (1997). Comparison of self-reported and database-linked family history of cancer data in a case-control study. American Journal of Epidemiology, 146, 244–248.CrossRefPubMed
Zurück zum Zitat Maddalena, A., Richards, C. S., McGinnis, M. J., Brothman, A., Desnick, R. J., Grier, R. E., et al. (2001). Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American college of medical genetics. Genetics in Medicine, 3, 200–205.CrossRefPubMedPubMedCentral Maddalena, A., Richards, C. S., McGinnis, M. J., Brothman, A., Desnick, R. J., Grier, R. E., et al. (2001). Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American college of medical genetics. Genetics in Medicine, 3, 200–205.CrossRefPubMedPubMedCentral
Zurück zum Zitat Maenner, M. J., Baker, M. W., Broman, K. W., Tian, J., Barnes, J. K., Atkins, A., et al. (2013). FMR1 GCC expansions: prevalence and sex ratios. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 162B, 466–735.CrossRef Maenner, M. J., Baker, M. W., Broman, K. W., Tian, J., Barnes, J. K., Atkins, A., et al. (2013). FMR1 GCC expansions: prevalence and sex ratios. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 162B, 466–735.CrossRef
Zurück zum Zitat Mailick, M. R., Hong, J., Pathouz, P., Baker, M. W., Greenberg, J. S., Smith, L., et al. (2014). Low-normal FMR1 CGG repeat length: phenotypic associations. Frontiers in Genetics, 5, 309.CrossRefPubMedPubMedCentral Mailick, M. R., Hong, J., Pathouz, P., Baker, M. W., Greenberg, J. S., Smith, L., et al. (2014). Low-normal FMR1 CGG repeat length: phenotypic associations. Frontiers in Genetics, 5, 309.CrossRefPubMedPubMedCentral
Zurück zum Zitat McCarty, C. A., Wilke, R. A., Giampietro, P. F., Wesbrook, S. D., & Caldwell, M. D. (2005). Marshfield clinic personalized medicine research project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Medicine, 2, 49–79.CrossRef McCarty, C. A., Wilke, R. A., Giampietro, P. F., Wesbrook, S. D., & Caldwell, M. D. (2005). Marshfield clinic personalized medicine research project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Medicine, 2, 49–79.CrossRef
Zurück zum Zitat Oktay, K., Kim, J. Y., Barad, D., & Babayev, S. N. (2010). Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology, 28, 240–244.CrossRefPubMed Oktay, K., Kim, J. Y., Barad, D., & Babayev, S. N. (2010). Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology, 28, 240–244.CrossRefPubMed
Zurück zum Zitat Park, L. S., Tate, J. P., Rodriguez-Barradas, M. C., Rimland, D., Bidwell Goetz, M., Gilbert, C., et al. (2014). Cancer incidence in HIV-infected versus uninfected veterans: Comparison of cancer registry and ICD-9 code diagnoses. J AIDS Clinical Research, 5, 1000318. Park, L. S., Tate, J. P., Rodriguez-Barradas, M. C., Rimland, D., Bidwell Goetz, M., Gilbert, C., et al. (2014). Cancer incidence in HIV-infected versus uninfected veterans: Comparison of cancer registry and ICD-9 code diagnoses. J AIDS Clinical Research, 5, 1000318.
Zurück zum Zitat Ricci, M. T., Pennese, L., Gismondi, V., Perfumo, C., Grasso, M., Gennaro, E., et al. (2014). The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations. European Journal of Human Genetics, 22, 280–282.CrossRefPubMed Ricci, M. T., Pennese, L., Gismondi, V., Perfumo, C., Grasso, M., Gennaro, E., et al. (2014). The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations. European Journal of Human Genetics, 22, 280–282.CrossRefPubMed
Zurück zum Zitat Seltzer, M. M., Baker, M. W., Hong, J., Maenner, M., Greenberg, J., & Mandel, D. (2012). Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 159, 589–597.CrossRef Seltzer, M. M., Baker, M. W., Hong, J., Maenner, M., Greenberg, J., & Mandel, D. (2012). Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 159, 589–597.CrossRef
Zurück zum Zitat Weghofer, A., Tea, M. K., Barad, D. H., Kim, A., Singer, C. F., Wagner, K., et al. (2012). BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 subgenotypes: explanation for the “BRCA paradox”? PloS One, 7, 1–7. Weghofer, A., Tea, M. K., Barad, D. H., Kim, A., Singer, C. F., Wagner, K., et al. (2012). BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 subgenotypes: explanation for the “BRCA paradox”? PloS One, 7, 1–7.
Metadaten
Titel
Is Low FMR1 CGG Repeat Length in Males Correlated with Family History of BRCA-Associated Cancers? An Exploratory Analysis of Medical Records
verfasst von
Hallee C. Adamsheck
Elizabeth M. Petty
Jinkuk Hong
Mei W. Baker
Murray H. Brilliant
Marsha R. Mailick
Publikationsdatum
30.06.2017
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 6/2017
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-017-0116-5

Weitere Artikel der Ausgabe 6/2017

Journal of Genetic Counseling 6/2017 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.